Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Neoplasms 1Liver Diseases 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × rubitecan × Clear all
NCT00113113 2024-08-02

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Astex Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled

Liver Diseases, Neoplasms, Renal Insufficiency

NCT00006047 2012-09-26

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
44 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡